Founded by
'There is an immense unmet need within the MS space with outdated diagnostic tools, a lack of technological advancement, and limited support in addressing neurodegenerative diseases. Octave's precision care solution is creating a new paradigm, where physicians and patients have a holistic view of a patient, their disease activity, and the impact of treatments on their disease progression,' said
'We appreciate Hikma Venture's thoughtful and collaborative approach in identifying and partnering with companies that have the potential to make a big impact in neurodegenerative diseases with novel digital health solutions,' said
MS is globally considered to be an important disease area with an underserved population and high unmet need ranging from diagnostics to care management. The challenges of this disease have been devastating and visible through misdiagnosis, difficulties in monitoring disease progression and evaluating the prescribed medication's efficacy. This has also been reflected in high failure rates for MS R&D clinical trials, which have been notoriously difficult to conduct.
Octave Bioscience will use the proceeds to support their commercialization efforts in MS and to explore expansion opportunities into other neurodegenerative diseases such as Parkinson's and Alzheimer's.
Contact:
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761
(C) 2023 Electronic News Publishing, source